COPENHAGEN, Denmark, May 13, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (ASND) today announced 2-year results from a post-hoc analysis of the Company’s Phase 3 PaTHway Trial demonstrating ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Palopegteriparatide improved skeletal dynamics and renal ...
Impaired coronary flow reserve in patients with metastatic cancer treated with sunitinib. Impact of the chronic kidney disease epidemiology collaboration (CKD-EPI) equation for estimating renal ...
Dawn Ethier, a police officer in Ottawa, Canada, recalls how her life revolved around managing her 100-pill-a-day regimen. Her symptoms began 3 weeks after her thyroid surgery, but it took another 4 ...
Mechanisms governing the antagonistic bone-promoting and bone-resorbing effects of parathyroid hormone induction are unclear. New study by researchers from Tokyo University of Science reveals a novel ...
We have successfully applied the radioimmunoassay for parathyroid hormone (PTH) to the localization of parathyroid adenomas by measurements of hormone concentration in multiple blood samples obtained ...
COPENHAGEN, Denmark, July 14, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from Week 156 of its Phase 3 PaTHway Trial confirming that long-term treatment with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results